Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q3 FY23 results · Oct–Dec 2022
Marksans Pharma reported revenue from operations of ₹479.83 crore (up 32.3% from Q3 FY22) and net profit of ₹62.31 crore (up 29.1% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 479.83 | 362.63 | +32.3% | 452.56 | +6.0% |
| Other income | 17.65 | 12.06 | +46.4% | 14.15 | +24.7% |
| Total income | 497.48 | 374.69 | +32.8% | 466.72 | +6.6% |
| Profit before tax | 79.20 | 60.35 | +31.2% | 77.83 | +1.8% |
| Net profit for the period | 62.31 | 48.27 | +29.1% | 60.12 | +3.6% |
| Attributable to shareholders of the company | 63.41 | — | — | 61.25 | +3.5% |
| EPS, basic (₹) | 1.56 | 1.20 | +30.0% | 1.52 | +2.6% |
| Net margin (%) | 13.0 | 13.3 | 13.3 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 172.75 | 165.94 | +4.1% | 170.26 | +1.5% |
| Other income | 15.71 | 12.06 | +30.2% | 21.03 | −25.3% |
| Total income | 188.46 | 178.00 | +5.9% | 191.29 | −1.5% |
| Profit before tax | 34.50 | 34.68 | −0.5% | 48.98 | −29.6% |
| Net profit for the period | 25.62 | 26.06 | −1.7% | 40.23 | −36.3% |
| EPS, basic (₹) | 0.63 | 0.64 | −1.6% | 1.00 | −37.0% |
| Net margin (%) | 14.8 | 15.7 | 23.6 |
Consolidated
- Filed with BSE
- 13 Feb 2023, 18:03 IST
- Board meeting
- 13 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2023, 18:03 IST
- Board meeting
- 13 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE